TB-500

Description

TB-500 – research-grade investigational peptide fragment

TB-500 commonly refers to an acetylated peptide fragment associated with thymosin beta-4 and containing the amino-acid sequence LKKTETQ. This sequence forms part of the actin-binding region of full-length thymosin beta-4. Because of this association, TB-500 is discussed in scientific research involving actin regulation, cellular migration, vascular signalling and tissue-remodelling pathways.

Within laboratory and preclinical research contexts, TB-500 is of interest due to research examining thymosin beta-4–related sequences and their interactions with endothelial cells and cytoskeletal processes. This makes it relevant for studies involving cell movement, angiogenic signalling, biological responses to tissue injury and associated repair mechanisms.

Research relevance of TB-500

TB-500 is commonly associated with:

• Investigation of actin-related cellular processes
• Studies involving endothelial-cell migration and adhesion
• Experimental analysis of angiogenic and vascular signalling
• Research into cytoskeletal organisation and cell motility
• Preclinical investigation of tissue-remodelling and repair pathways

Scientific research background

Scientific studies of the LKKTETQ actin-binding region of thymosin beta-4 have examined endothelial-cell migration, adhesion, tubule formation and angiogenic activity. Separate research involving full-length thymosin beta-4 has investigated cell migration, wound repair, vascular development and tissue-regeneration processes in cultured cells and animal models.

TB-500 should not automatically be treated as equivalent to full-length thymosin beta-4. Published research may examine the complete 43-amino-acid thymosin beta-4 molecule rather than the shorter TB-500-associated fragment. The exact sequence, molecular identity and purity of material marketed as TB-500 should therefore be confirmed through supplier documentation and analytical testing.

Available evidence concerning TB-500 remains predominantly laboratory-based and preclinical. Results depend on the specific peptide sequence, experimental model, research conditions, concentration, methodology and measured endpoints. These findings should not be interpreted as confirmed therapeutic outcomes in humans.

Scientific reference

Philp D et al. The actin binding site on thymosin beta-4 promotes endothelial cell migration and angiogenesis. FASEB Journal, 2003.

FOR RESEARCH USE ONLY

IMPORTANT INFORMATION

• This substance is supplied strictly for laboratory research purposes.
• It is not a food product.
• It is not a dietary supplement.
• It is not an authorised medicinal product.
• It is not intended for human or animal consumption.
• The product name does not by itself confirm the peptide sequence, identity or purity.
• Keep out of reach of children.
• Keep the container sealed when not in use.
• Store in the original container only.
• Store according to the conditions stated on the product label or certificate of analysis.
• Protect from moisture, excessive heat and direct sunlight.
• Avoid handling during pregnancy or breastfeeding.

In the event of accidental exposure, irritation, illness or any adverse reaction, seek medical advice.